The abstract is read at the publisher; the summary is JClub's.
HDAC inhibitor–venetoclax combinations are mechanistically rational in acute myeloid leukaemia, with chidamide-based CACAG-VEN reporting overall response rates of 76.5–98.0%.
- Why it matters: Venetoclax plus hypomethylating agents improves outcomes in older or unfit AML, yet resistance and relapse remain common. This review addresses the need for validated partner strategies beyond incomplete, context-dependent HDAC mechanisms.
- What they did: It analyzes rationale for pairing venetoclax with HDAC inhibitors, emphasizing Class I HDAC1/2/3 effects on myeloid cell leukaemia 1 and BH3-only gene de-repression, while noting context-dependent alternatives. It also summarizes early chidamide-based CACAG-VEN composite regimens and their reported response and MRD ranges.
- The result: Across early composite regimens, complete remission/composite complete remission rates reach 73.5–93.3% and measurable residual disease negativity is 44–61%. The review concludes that standard-of-care use needs biomarker-selected, randomized or pharmacodynamic validation while controlling non-HDAC components and accounting for cytochrome P450 3A interactions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.